Towards prevention of chronic auto-immune disease: dominant B-cell receptor clones predict the onset of rheumatoid arthritis

Recruiting

• Conditions: rheumatism; rheumatoid arthritis; 10003816; 10023213

• Registration Number: NL-OMON45295
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 75

Inclusion Criteria

Male and female patients of more than 18 years old diagnosed with arthralgia and anti-citrullinated peptide antibodies and/ or rheumatoid factor.
- Having given written informed consent prior to undertaking any study-related procedures.
- Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research.

Exclusion Criteria

- Under any administrative or legal supervision.
- Conditions/situations such as:
• Patients with conditions/concomitant diseases making them non evaluable for the primary endpoint
• Impossibility to meet specific protocol requirements (e.g. blood sampling)
• Patient is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
• Uncooperative or any condition that could make the patient potentially non-compliant to the study procedures

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The inclusion of approximately 75 individuals who have RA associated<br /><br>autoantibodies and arthralgia, in whom we successfully collect blood (and<br /><br>tissue) samples to study dominant clones. Completion of the study period or<br /><br>development of RA will mean the end of the study. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-</p><br>